News
INMB
1.030
-1.90%
-0.020
INmune Bio Price Target Cut to $2.50/Share From $4.00 by Freedom Broker
Dow Jones · 4h ago
INmune Bio Is Maintained at Buy by Freedom Broker
Dow Jones · 4h ago
Freedom Broker Maintains Buy on INmune Bio, Lowers Price Target to $2.5
Benzinga · 4h ago
INmune Bio price target lowered to $2.50 from $4 at Freedom Broker
TipRanks · 10h ago
INmune Bio Advances Ebstrocel Toward 2027 Approval as Financing and Pipeline Strengthen Outlook
TipRanks · 2d ago
QUBT Stock Drops 4% After Earnings Despite 2,374% Q3 Revenue Surge
TipRanks · 3d ago
Weekly Report: what happened at INMB last week (1102-1106)?
Weekly Report · 4d ago
INmune Bio (INMB) Q3 2026 Earnings Call Transcript
The Motley Fool · 11/06 17:17
INmune Bio GAAP EPS of -$0.17 misses by $0.02
Seeking Alpha · 11/05 22:23
INmune Bio Q3 2026 Earnings Call Transcript
Benzinga · 11/05 22:04
INmune Bio Q3 EPS $(0.17) Misses $(0.15) Estimate
Benzinga · 11/05 21:01
*INmune Bio 3Q Loss/Shr 17c >INMB
Dow Jones · 11/05 21:00
Press Release: INmune Bio Inc. Announces Third Quarter 2026 Results and Provides Business Update
Dow Jones · 11/05 21:00
Press Release: INmune Bio Inc. Announces Third -3-
Dow Jones · 11/05 21:00
Press Release: INmune Bio Inc. Announces Third -2-
Dow Jones · 11/05 21:00
Weekly Report: what happened at INMB last week (1026-1030)?
Weekly Report · 11/02 09:46
INmune Bio, Inc. Enters Securities Purchase Agreement for $4.5 million Registered Direct Offering
NASDAQ · 10/29 19:22
Inmune Bio Announces New Equity Financing Agreement
TipRanks · 10/29 11:57
INmune Bio prices $4.5M registered direct offering and private placement
Seeking Alpha · 10/28 12:43
Weekly Report: what happened at INMB last week (1019-1023)?
Weekly Report · 10/26 09:46
More
Webull provides a variety of real-time INMB stock news. You can receive the latest news about Inmune Bio Inc through multiple platforms. This information may help you make smarter investment decisions.
About INMB
INmune Bio Inc. is a clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. The Company has three product platforms. The Dominant-Negative Tumor Necrosis Factor (DN-TNF) product platform utilizes dominant-negative technology to selectively neutralize soluble TNF. DN-TNF product candidates are in clinical trials to determine if they can treat Mild Alzheimer’s disease, Mild Cognitive Impairment and treatment-resistant depression (XPro). The Natural Killer Cell Priming Platform includes INKmune, developed to prime a patient’s NK cells to eliminate minimal residual disease in patients with cancer and is in trials in metastatic castration-resistance prostate cancer. The third program, CORDStrom, is a proprietary pooled, allogeneic, human umbilical cord-derived mesenchymal Stromal/Stem cell (hucMSCs) platform that has completed a trial in recessive dystrophic epidermolysis bullosa.